{"id":"https://openalex.org/W2025328110","doi":"https://doi.org/10.1089/dia.2011.0117","title":"Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes from Subcutaneous Injection of Insulin Lispro with Hyaluronidase","display_name":"Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes from Subcutaneous Injection of Insulin Lispro with Hyaluronidase","publication_year":2011,"publication_date":"2011-12-03","ids":{"openalex":"https://openalex.org/W2025328110","doi":"https://doi.org/10.1089/dia.2011.0117","mag":"2025328110","pmid":"https://pubmed.ncbi.nlm.nih.gov/22136324"},"language":"en","primary_location":{"id":"doi:10.1089/dia.2011.0117","doi":"https://doi.org/10.1089/dia.2011.0117","is_oa":false,"landing_page_url":"https://doi.org/10.1089/dia.2011.0117","pdf_url":null,"source":{"id":"https://openalex.org/S67495602","display_name":"Diabetes Technology & Therapeutics","issn_l":"1520-9156","issn":["1520-9156","1557-8593"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Technology &amp; Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044166679","display_name":"Marcus Hompesch","orcid":"https://orcid.org/0000-0001-5867-2131","observed_orcids":["https://orcid.org/0000-0001-5867-2131"]},"institutions":[{"id":"https://openalex.org/I4210134048","display_name":"Profil Institute for Clinical Research","ror":"https://ror.org/03f2dkv17","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210134048"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marcus Hompesch","raw_affiliation_strings":["Profil Institute for Clinical Research, Chula Vista, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Profil Institute for Clinical Research, Chula Vista, California","institution_ids":["https://openalex.org/I4210134048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013159981","display_name":"Douglas B. Muchmore","orcid":"https://orcid.org/0000-0002-9300-3862","observed_orcids":["https://orcid.org/0000-0002-9300-3862"]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas B. Muchmore","raw_affiliation_strings":["Halozyme Therapeutics Inc, San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Halozyme Therapeutics Inc, San Diego, California","institution_ids":["https://openalex.org/I4210088034"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084625858","display_name":"Linda Morrow","orcid":"https://orcid.org/0000-0003-3252-4477","observed_orcids":["https://orcid.org/0000-0003-3252-4477"]},"institutions":[{"id":"https://openalex.org/I4210134048","display_name":"Profil Institute for Clinical Research","ror":"https://ror.org/03f2dkv17","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210134048"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Linda Morrow","raw_affiliation_strings":["Profil Institute for Clinical Research, Chula Vista, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Profil Institute for Clinical Research, Chula Vista, California","institution_ids":["https://openalex.org/I4210134048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011791624","display_name":"Elizabeth A. Ludington","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Ludington","raw_affiliation_strings":["Halozyme Therapeutics Inc, San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Halozyme Therapeutics Inc, San Diego, California","institution_ids":["https://openalex.org/I4210088034"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109281700","display_name":"Daniel E. Vaughn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Daniel E. Vaughn","raw_affiliation_strings":["Halozyme Therapeutics Inc, San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Halozyme Therapeutics Inc, San Diego, California","institution_ids":["https://openalex.org/I4210088034"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5109281700"],"corresponding_institution_ids":["https://openalex.org/I4210088034"],"apc_list":null,"apc_paid":null,"fwci":2.2595,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.87028008,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"14","issue":"3","first_page":"218","last_page":"224"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.8026999831199646,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.8026999831199646,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.18479999899864197,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/insulin-lispro","display_name":"insulin lispro","score":0.7269999980926514},{"id":"https://openalex.org/keywords/recombinant-human-hyaluronidase","display_name":"recombinant human hyaluronidase","score":0.949999988079071},{"id":"https://openalex.org/keywords/rhuph20","display_name":"rHuPH20","score":0.8790000081062317},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9350000023841858},{"id":"https://openalex.org/keywords/postprandial-glycemic-control","display_name":"postprandial glucose control","score":0.9179999828338623},{"id":"https://openalex.org/keywords/insulin-pharmacokinetics","display_name":"insulin pharmacokinetics","score":0.9110000133514404},{"id":"https://openalex.org/keywords/insulin-absorption","display_name":"insulin absorption","score":0.7129999995231628},{"id":"https://openalex.org/keywords/regular-insulin","display_name":"regular insulin","score":0.6639999747276306},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.8560000061988831},{"id":"https://openalex.org/keywords/hyperglycemia","display_name":"hyperglycemia","score":0.8080000281333923},{"id":"https://openalex.org/keywords/subcutaneous-insulin-injection","display_name":"subcutaneous insulin injection","score":0.7160000205039978},{"id":"https://openalex.org/keywords/meal-tolerance-test","display_name":"meal tolerance test","score":0.4230000078678131}],"concepts":[{"id":"https://openalex.org/C2776486108","wikidata":"https://www.wikidata.org/wiki/Q3492616","display_name":"Insulin lispro","level":4,"score":0.9264702796936035},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.9146847724914551},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8965247869491577},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.8279573917388916},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.6490305066108704},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6207641959190369},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6011618971824646},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.6007475256919861},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.5666753053665161},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5666317343711853},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5584967732429504},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.5049613118171692},{"id":"https://openalex.org/C2779946736","wikidata":"https://www.wikidata.org/wiki/Q2893248","display_name":"Regular insulin","level":4,"score":0.4936622083187103},{"id":"https://openalex.org/C2781232474","wikidata":"https://www.wikidata.org/wiki/Q124407","display_name":"Type 1 diabetes","level":3,"score":0.49336400628089905},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.09813559055328369},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006821","descriptor_name":"Hyaluronoglucosaminidase","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006821","descriptor_name":"Hyaluronoglucosaminidase","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006821","descriptor_name":"Hyaluronoglucosaminidase","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019518","descriptor_name":"Postprandial Period","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061268","descriptor_name":"Insulin Lispro","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061268","descriptor_name":"Insulin Lispro","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D061268","descriptor_name":"Insulin Lispro","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D061386","descriptor_name":"Insulin, Regular, Human","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061386","descriptor_name":"Insulin, Regular, Human","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D061386","descriptor_name":"Insulin, Regular, Human","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1089/dia.2011.0117","doi":"https://doi.org/10.1089/dia.2011.0117","is_oa":false,"landing_page_url":"https://doi.org/10.1089/dia.2011.0117","pdf_url":null,"source":{"id":"https://openalex.org/S67495602","display_name":"Diabetes Technology & Therapeutics","issn_l":"1520-9156","issn":["1520-9156","1557-8593"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Technology &amp; Therapeutics","raw_type":"journal-article"},{"id":"pmid:22136324","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22136324","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes technology & therapeutics","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320315641","display_name":"Halozyme","ror":"https://ror.org/001x5ea44"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W97375214","https://openalex.org/W1586699825","https://openalex.org/W1967649339","https://openalex.org/W1968202154","https://openalex.org/W1988541637","https://openalex.org/W1998735874","https://openalex.org/W2005061722","https://openalex.org/W2007003907","https://openalex.org/W2009795996","https://openalex.org/W2030768028","https://openalex.org/W2041489038","https://openalex.org/W2052047217","https://openalex.org/W2057595002","https://openalex.org/W2058804545","https://openalex.org/W2081528927","https://openalex.org/W2092653445","https://openalex.org/W2110427985","https://openalex.org/W2111777136","https://openalex.org/W2113469642","https://openalex.org/W2121848292","https://openalex.org/W2122188282","https://openalex.org/W2126781806","https://openalex.org/W2129512027","https://openalex.org/W2158548553","https://openalex.org/W2181049752","https://openalex.org/W2191569664","https://openalex.org/W2596624061","https://openalex.org/W4242554702"],"related_works":["https://openalex.org/W2111777136","https://openalex.org/W7100283469","https://openalex.org/W2171453611","https://openalex.org/W2122188282","https://openalex.org/W1968202154","https://openalex.org/W2312323002","https://openalex.org/W1985158279","https://openalex.org/W2029160074","https://openalex.org/W2057971952","https://openalex.org/W2050322512"],"abstract_inverted_index":{"BACKGROUND:":[0],"Coinjection":[1],"of":[2,31,76,87,91,102,105,124,150,160,181,197,214,229,267],"hyaluronidase":[3,47],"has":[4],"been":[5],"shown":[6],"to":[7,25,69,129,133,207,239,252],"accelerate":[8],"insulin":[9,40,52,64,135,253,257,276],"absorption":[10],"in":[11,78,118,145],"healthy":[12],"volunteers":[13],"and":[14,43,49,66,93,153,184,248,278],"patients":[15,32,80,206],"with":[16,33,42,54,81,142,242,271,274],"type":[17,34],"1":[18],"diabetes":[19,36],"mellitus.":[20],"This":[21,57],"study":[22,61],"was":[23,108,231],"undertaken":[24],"compare":[26],"the":[27,63,111,146,173,189,209],"postprandial":[28,99],"glycemic":[29,268],"response":[30,68],"2":[35,157],"mellitus":[37],"(T2DM)":[38],"administered":[39],"lispro":[41,130,230,254,272],"without":[44,219,237],"recombinant":[45],"human":[46,51],"(rHuPH20)":[48],"regular":[50],"(RHI)":[53],"rHuPH20.":[55],"METHODS:":[56],"double-blind":[58],"three-way":[59],"crossover":[60],"compared":[62,270],"pharmacokinetics":[65,127,165],"glucodynamic":[67],"a":[70,114],"standardized":[71],"liquid":[72],"meal":[73],"(80":[74],"g":[75],"carbohydrate)":[77],"21":[79],"T2DM":[82],"who":[83],"received":[84],"subcutaneous":[85],"injections":[86],"individually":[88],"optimized":[89],"doses":[90,250],"lispro\u00b1rHuPH20":[92],"RHI+rHuPH20.":[94],"The":[95,225],"optimum":[96,227,249],"dose":[97,228],"(targeting":[98],"glucose":[100,221],"[PPG]":[101],"70-140":[103],"mg/dL)":[104],"each":[106],"preparation":[107],"selected":[109],"by":[110],"investigator":[112],"following":[113],"fixed-dose":[115],"escalation":[116],"procedure":[117],"three":[119,202],"dose-finding":[120],"meals.":[121],"RESULTS:":[122],"Co-injection":[123],"lispro+rHuPH20":[125],"accelerated":[126,164],"relative":[128],"alone":[131],"(time":[132],"peak":[134,215],"concentration,":[136],"43":[137],"vs.":[138],"74":[139],"min;":[140],"P=0.0045)":[141],"increased":[143],"exposure":[144,155],"first":[147],"hour":[148],"(184%":[149],"control;":[151,161,182,198],"P<0.0001)":[152],"reduced":[154,232,279],"after":[156],"h":[158,177,193],"(67%":[159],"P=0.0001).":[162],"These":[163],"improved":[166],"both":[167],"total":[168],"hyperglycemic":[169],"excursions":[170,186],"(area":[171,187],"under":[172,188],"curve":[174,190],"for":[175,191,223],"0-4":[176],">140":[178],"mg/dL,":[179,195],"56%":[180],"P=0.048)":[183],"hypoglycemic":[185,280],"0-8":[192],"<70":[194],"34%":[196],"P=0.033),":[199],"allowing":[200],"over":[201],"times":[203],"as":[204],"many":[205],"reach":[208],"American":[210],"Diabetes":[211],"Association's":[212],"target":[213],"PPG":[216],"<180":[217],"mg/dL":[218],"requiring":[220],"treatment":[222],"hypoglycemia.":[224],"mean":[226],"8%":[233],"from":[234],"0.275":[235],"U/kg":[236,241],"rHuPH20":[238,243],"0.254":[240],"(P=0.04).":[244],"RHI+rHuPH20":[245],"had":[246],"responses":[247],"comparable":[251],"alone.":[255],"All":[256],"preparations":[258],"were":[259],"well":[260],"tolerated.":[261],"CONCLUSIONS:":[262],"Lispro+rHuPH20":[263],"provided":[264],"superior":[265],"control":[266],"excursion":[269],"alone,":[273],"lower":[275],"requirements":[277],"excursions.":[281]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}